Influence of Vorapaxar on Thrombin Generation and Coagulability
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
This investigation will be conducted in patients 18-75 years of age with multiple coronary
artery disease risk factors (antiplatelet naïve patients) and patients with prior MI or PVD
on antiplatelet therapy. Pharmacodynamics will be assessed at multiple time points to assess
onset-, maintenance-, and offset-effect of vorapaxar on thrombin generation, platelet
reactivity, and plasma/platelet endothelial and inflammatory biomarkers. Safety assessment
will be assessed throughout the study.